Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA Back

Long Acting HIV ART - is this the future? Nanoformulations - Implants       talk at CROI by Flexner: LONG-ACTING ANTIRETROVIRAL THERAPY: A SHOT IN THE DARK OR A PARADIGM SHIFT? [for HIV & HCV ?]   - they have formed LEAP - Long Acting Extended Release ART Resource Program with researchers/community and pharmaceutical industry me members including Flexner http://longactinghiv.org/   Charles W Flexner Johns Hopkins University, Baltimore, MD, USA http://www.croiwebcasts.org/console/player/33659?mediaType=slideVideo&   Albuvertide is long acting T20 -Presented at Glasgow2016 : Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48 week results from the randomized, controlled, phase 3, non-inferiority TALENT study http://www.natap.org/2016/GLASGOW/GLASGOW_38.htm   EFdA/MK8591 is new Merck NRTI - data suggest potential for up to 1 year /implant - http://natap.org/2016/CROI/croi_14.htm   -CROI: MK-8591 Concentrations at Sites of HIV Transmission and Replication http://www.natap.org/2016/HIV/080516_03.htm   CROI: LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY   New Gilead Capsid Inhibitor for HIV - (02/16/17)   CROI: Discovery of Novel Potent HIV Capsid Inhibitors with Long-Acting Potential   - Injectable Cabotegravir+Rilpivirine -   CROI:Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy   CROI: A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY - (02/23/17)   TAF IMPLANT - CROI: In Vitro -In Vivo Evaluation of a Biodegradable Implant Containing TAF for HIV PrEP